Two Drug Companies Unite for All-Oral Hep C Regimen
Pharmasset inks collaborative deal with J&J unit to develop hep C combo drug
July 6, 2011 by Brad Lemaire
Pharmasset (NASDAQ:VRUS) reported Wednesday it signed a collaboration agreement with pharmaceutical company Tibotec, a Johnson & Johnson (NYSE:JNJ) unit, to conduct clinical trials to develop an all-oral treatment for hepatitis C.
The study, which is slated to begin later this year, will assess the potential of Pharmasset’s drug PSI-7977, in combination with Tibotec’s TMC435, to achieve “sustained virologic response” 12 weeks post treatment, in patients infected with hepatitis C.
Princeton, New Jersey-based Pharmasset said the trial will also assess the safety and effects after 12 and 24 weeks of the combined treatment. Some patients will also take ribavirin in addition to PSI-7977 and TMC435.
Continue reading this entire article: